Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CVS Health (CVS) Gets a Buy from Bernstein

Tipranks - Tipranks - Wed Apr 1, 11:45AM CDT

Bernstein analyst Courtney Breen maintained a Buy rating on CVS Health yesterday and set a price target of $94.00.

End of Quarter Sale - 50% Off TipRanks

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company. According to TipRanks, Breen has an average return of 19.4% and an 84.09% success rate on recommended stocks.

In addition to Bernstein, CVS Health also received a Buy from Piper Sandler’s Jessica Tassan in a report issued today. However, on March 20, TipRanks – xAI reiterated a Hold rating on CVS Health (NYSE: CVS).

See the top stocks recommended by analysts >>

Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).